Get the Stockscreener App
0.2129
11.92%
-0.0288
After Hours:
.20
-0.0129
-6.06%
Cosmos Health Inc stock is traded at $0.2129, with a volume of 16.18M.
It is down -11.92% in the last 24 hours and down -27.51% over the past month.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
See More
Previous Close:
$0.2417
Open:
$0.2109
24h Volume:
16.18M
Relative Volume:
3.59
Market Cap:
$13.22M
Revenue:
$69.49M
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.328
EPS:
-0.649
Net Cash Flow:
$-14.46M
1W Performance:
+3.35%
1M Performance:
-27.51%
6M Performance:
-58.01%
1Y Performance:
-50.74%
1-Day Range:
$0.1831
$0.2197
1-Week Range:
$0.1831
$0.2791
52-Week Range:
$0.1831
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2129 | 15.00M | 69.49M | -21.13M | -14.46M | -0.649 |
MCK
Mckesson Corp
|
750.63 | 91.30B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
271.83 | 53.91B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
221.77 | 53.00B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
79.92 | 9.11B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.34 | 1.05B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Stock (COSM) Latest News
CosmoFarm's Robotic Rise: A Lifeline for Financially Strained Cosmos Health? - BriefGlance
CosmoFarm delivers record Q2 2026 revenue of over $15 million - scanx.trade
Cosmos Health Reports Record Q2 Revenue for CosmoFarm, Exceeds $60 Million Annualized Run Rate - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Cosmos Health Inc (COSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cosmos Health Inc (COSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cosmos Health Inc (COSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cosmos Health enters skincare market with new product line - Investing.com
Cosmos Health enters skincare market with new product line By Investing.com - Investing.com India
Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Cosmos Health Inc (COSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cosmos Health Inc (COSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cosmos Health signs five-year manufacturing deal with Pharmex - Investing.com
Cosmos Health lands five-year deal to make 2.86 million drug units - Stock Titan
Cosmos Health (COSM) CFO swaps $42K company debt for 168,135 shares - Stock Titan
Cosmos Health Inc (COSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States - marketscreener.com
Cosmos Health projects $22.7M revenue from U.S. product line - Investing.com UK
Cosmos Health Provides Update on United States Portfolio; - GlobeNewswire
Cosmos Health projects $22.7M revenue from U.S. product line By Investing.com - Investing.com Canada
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit - marketscreener.com
Science-driven 18 Series aims for $17M profit in U.S. launch - Stock Titan
$Cosmos Health (COSM.US)$ just waiting to see better volume - Moomoo
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Cosmos Health (COSM) Secures New Contract Manufacturing Orders - GuruFocus
Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines - marketscreener.com
Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines - GlobeNewswire
Cosmos Health Stock (COSM) Opinions on EU Expansion and Antiseptic Sales Growth - Quiver Quantitative
Cosmos Health (NASDAQ: COSM) CEO swaps $45K company debt for shares - Stock Titan
Cosmos Health sets three-year targets for antiseptic brands By Investing.com - Investing.com Australia
Cosmos Health sets three-year targets for antiseptic brands - Investing.com
C-Scrub antiseptic tops $1.5M, aims for $7.4M across Europe - Stock Titan
Cosmos Health (NASDAQ: COSM) CEO gets 701K shares for $160K debt - Stock Titan
Cosmos Health Signs Letter of Intent to Buy Doc Pharma - Moomoo
Cosmos Health (COSM) Plans Acquisition of Doc Pharma - GuruFocus
Cosmos Health director awarded 20,000 shares | COSM Insider Trading - Stock Titan
Cosmos Health (NASDAQ: COSM) director receives 20,000-share equity award via RSU conversion - Stock Titan
Cosmos Health (NASDAQ: COSM) awards Demetriades 20K shares, now holding 55K - Stock Titan
Director at Cosmos Health (NASDAQ: COSM) awarded 40,000 shares - Stock Titan
Cosmos Health (COSM) grants 20,000 shares of stock to director - Stock Titan
Cosmos Health (NASDAQ: COSM) CFO receives 850K-share equity award via RSU conversion - Stock Titan
Cosmos Health (COSM) CEO awarded 2.35M shares via RSU conversion - Stock Titan
Cosmos Health Inc. Announces Proposed Acquisition of Doc Pharma S.A. to Enhance Vertical Integration and Product Portfolio - Quiver Quantitative
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio - The Manila Times
Cosmos Health pursues Doc Pharma deal, adding $6.7M in sales - Stock Titan
Cosmos Health Secures Additional 180-Day Nasdaq Extension To Regain Bid Price Compliance - TradingView
Cosmos Health gets Nasdaq extension to regain $1 minimum bid price - Investing.com Nigeria
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance - The Manila Times
Cosmos Health gets Dec. 7 deadline from Nasdaq; reverse split only last resort - Stock Titan
Cosmos Health (COSM) Secures Manufacturing Deal with Verisfield S.A. - GuruFocus
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.78%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):